@gregoryai.bsky.socialNeurodegenerative diseases (NDs), such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are characterized by progressive neuronal loss, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Novel neuroprotectiv...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
@reenie.bsky.socialI put on my leopard print workout outfit, a mismatched red Canada sweater & started striking funny poses for my husband.
Then my MS kicked in and I lost my balance and almost fell.
Totally sexy.
We both laughed at my awkwardness.
Anyhew… time to hit the gym.
@abudd.bsky.social@gregoryai.bsky.socialNew clinical trial
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
@gregoryai.bsky.socialNew clinical trial
A Prospective Longitudinal Multicenter, Multi-Country, Observational Study Assessing Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Relapsing-Remitting Multiple Sclerosis (SONATA-MS)
@neurologyadvisor.bsky.socialReductions in serum glial fibrillary acidic protein levels during disease-modifying #therapy were associated with a decreased risk for subsequent disease progression in patients with #MultipleSclerosis.
https://www.neurologyadvisor.com/news/elevated-serum-gfap-multiple-sclerosis-progression-risk/
@msnewstoday.bsky.socialGet the scoop: https://bit.ly/46sfWCW
Greater disability levels are associated with more severe depression among people with RRMS, according to a study in Egypt.
@taneuroldisord.bsky.socialWhat is the real-world safety and efficacy of #siponimod in secondary progressive #MultipleSclerosis? Findings from the RESYZE study:
@chwaykai.bsky.socialYep, it's infusion day.... #tysabri #fums #multiplesclerosis
@abudd.bsky.social@abudd.bsky.social
@wheelieoutthere.bsky.socialTracey W. of Mount Vernon, NY, had never seen people living with #MultipleSclerosis represented onstage. So, she wrote and staged a play doing just that.
UNBROKEN VOICES shares authentic stories and people living with MS, raising awareness and helping audiences better understand life with MS.
@gregoryai.bsky.socialNew clinical trial
Prevalence of Primary Headache Among Patients With Multiple Sclerosis in Assiut University Hospitals
@msnewstoday.bsky.socialGet the scoop: https://bit.ly/4rfGmkM
Medically indicated C-sections before full term pregnancy may be more frequent among patients with MS, a study suggests.
@vaccinologist.bsky.socialNew Nature Medicine study strengthens the mechanistic link between #EpsteinBarrvirus #EBV and #multiplesclerosis relapse. Researchers detected increased EBV activity in B cells up to 3 months before relapse, activation of MS-risk genes & expansion of ABC-like B cells www.linkedin.com/posts/drmelv...
@kevjbyrne.bsky.socialRecognize warning sign before it’s too late. If you see it in yourself, act. If you see it in someone else, reach out! Together, we can get through this with nothing but smiles! #NeverStopNeverQuitForThem #MultipleSclerosis #WorldSuicidePreventionDay #VeteranSuicidePrevention #VetsReachOut
@msnewstoday.bsky.socialDiscover more: https://bit.ly/4iFEQGB
Epstein-Barr virus reactivation in immune cells may trigger disease flares in multiple sclerosis, a study suggested.
@thetorontonian.bsky.social#CanadianNEWS 🍁 #MultipleSclerosis Researchers at the University of Manitoba have found that restoring levels of a depleted brain protein called neuregulin-1 (Nrg-1) may help repair damaged brain tissue, slow or halt the progression of multiple sclerosis!
www.ctvnews.ca/health/artic...
@gregoryai.bsky.socialNew clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Trial of PRO-1562 in Healthy Adults and Adults With Multiple Sclerosis and Chronic Optic Neuropathy
@gregoryai.bsky.socialNew clinical trial
Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy